Page last updated: 2024-09-05

deferasirox and dihydropyridines

deferasirox has been researched along with dihydropyridines in 3 studies

Compound Research Comparison

Studies (deferasirox)	Trials (deferasirox)	Recent Studies (post-2010) (deferasirox)	Studies (dihydropyridines)	Trials (dihydropyridines)	Recent Studies (post-2010) (dihydropyridines)
832	136	572	5,022	529	969

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Acklin, P; Alberti, D; Buehlmayer, P; Hauffe, S; Lattmann, R; Nick, H; Schupp, J	1
Hider, RC; Zhou, T	1
Chattipakorn, N; Chattipakorn, SC; Fucharoen, S; Kumfu, S	1

Reviews

1 review(s) available for deferasirox and dihydropyridines

Article	Year
Development of tridentate iron chelators: from desferrithiocin to ICL670. Current medicinal chemistry, 2003, Volume: 10, Issue:12 Topics: Animals; Benzoates; Callithrix; Chemical Phenomena; Chemistry, Physical; Deferasirox; Dihydropyridines; Dogs; Humans; Iron; Iron Chelating Agents; Rats; Thiazoles; Triazoles	2003

Other Studies

2 other study(ies) available for deferasirox and dihydropyridines

Article	Year
The design of orally active iron chelators. Annals of the New York Academy of Sciences, 2005, Volume: 1054 Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Dihydropyridines; Drug Design; Drug Evaluation, Preclinical; Humans; Iron; Iron Chelating Agents; Ligands; Models, Molecular; Molecular Structure; Oxidation-Reduction; Pyridones; Thiazoles; Triazoles	2005
Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Experimental physiology, 2016, Volume: 101, Issue:4 Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles	2016

Article

Year

The design of orally active iron chelators.

Annals of the New York Academy of Sciences, 2005, Volume: 1054

Topics: Administration, Oral; Benzoates; Clinical Trials as Topic; Deferasirox; Dihydropyridines; Drug Design; Drug Evaluation, Preclinical; Humans; Iron; Iron Chelating Agents; Ligands; Models, Molecular; Molecular Structure; Oxidation-Reduction; Pyridones; Thiazoles; Triazoles

2005

Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.

Experimental physiology, 2016, Volume: 101, Issue:4

Topics: Animals; Benzoates; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cardiovascular Diseases; Deferasirox; Deferiprone; Deferoxamine; Dihydropyridines; Heart; Iron Chelating Agents; Iron Overload; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Mitochondria; Nitrophenols; Organophosphorus Compounds; Pyridones; Thalassemia; Triazoles

2016